Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$42.96 USD
-0.79 (-1.81%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $42.94 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Kymera Therapeutics, Inc.'s return on equity, or ROE, is -30.11% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that KYMR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
KYMR 42.96 -0.79(-1.81%)
Will KYMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Other News for KYMR
Kymera Therapeutics (KYMR) Gains Support as Data Release Approaches
Kymera Therapeutics transferred with Buy rating at B. Riley
Goldman Sachs Initiates Coverage on Kymera Therapeutics (KYMR) as Early-Stage Biotech | KYMR ...
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
Gilead sees Q2 EPS hit from IPR&D expenses